Abstract:Fabry disease (FD) is a recessive monogenic disease linked to chromosome X due to more than two hundred mutations in the alfa-galactosidase A (GLA) gene. Modifications of the GLA gene may cause the progressive accumulation of globotriaosylceramide (Gb3) and its deacylated form, globotriasylsphingosine (lyso-Gb3), in lysosomes of several types of cells of the heart, kidneys, skin, eyes, peripheral and central nervous system (not clearly and fully demonstrated), and gut with different and pleiotropic clinical symptoms. Among the main symptoms are acroparesthesias and pain crisis (involving the peripheral nervous system), hypohidrosis, abdominal pain, gut motility abnormalities (involving the autonomic system), and finally, cerebrovascular ischemic events due to macrovascular involvement (TIA and stroke) and lacunar strokes and white matter abnormalities due to a small vessel disease (SVS). Gb3 lysosomal accumulation causes cytoplasmatic disruption and subsequent cell death. Additional consequences of Gb3 deposits are inflammatory processes, abnormalities of leukocyte function, and impaired trafficking of some types of immune cells, including lymphocytes, monocytes, CD8+ cells, B cells, and dendritic cells. The involvement of inflammation in AFD pathogenesis conflicts with the reported poor correlation between CRP levels as an inflammation marker and clinical scores such as the Mainz Severity Score Index (MSSI). Also, some authors have suggested an autoimmune reaction is involved in the disease's pathogenetic mechanism after the α-galactosidase A deficiency. Some studies have reported a high degree of neuronal apoptosis inhibiting protein as a critical anti-apoptotic mediator in children with Fabry disease compared to healthy controls. Notably, this apoptotic upregulation did not change after treatment with enzymatic replacement therapy (ERT), with a further upregulation of the apoptosis-inducing factor after ERT started. Gb3-accumulation has been reported to increase the degree of oxidative stress indexes and the production of reactive oxygen species (ROS). Lipids and proteins have been reported as oxidized and not functioning. Thus, neurological complications are linked to different pathogenetic molecular mechanisms. Progressive accumulation of Gb3 represents a possible pathogenetic event of peripheral nerve involvement. In contrast, central nervous system participation in the clinical setting of cerebrovascular ischemic events seems to be due to the epitheliopathy of Anderson-Fabry disease with lacunar lesions and white matter hyperintensities (WMHs). In this review manuscript, we revised molecular mechanisms of peripheral and central neurological complications of Anderson-Fabry Disease. The management of Fabry disease may be improved by the identification of biomarkers that reflect the clinical course, severity, and progression of the disease. Intensive research on biomarkers has been conducted over the years to detect novel markers that may potentially be used in clinical practice as a screening tool, in the context of the diagnostic process and as an indicator of response to treatment. Recent proteomic or metabolomic studies are in progress, investigating plasma proteome profiles in Fabry patients: these assessments may be useful to characterize the molecular pathology of the disease, improve the diagnostic process, and monitor the response to treatment.

The Role of Cardiac Imaging in the Diagnosis and Management of Anderson-Fabry Disease

Cardiac involvement in Anderson–Fabry disease. The role of advanced echocardiography

Anderson-Fabry disease cardiomyopathy: an update on epidemiology, diagnostic approach, management and monitoring strategies

#3394 THE VALUE OF ADVANCED CARDIAC MAGNETIC RESONANCE IN DETECTING THE CHARACTERISTICS OF CARDIAC INVOLVEMENT IN ANDERSON-FABRY DISEASE

Anderson–Fabry disease management: role of the cardiologist

Anderson–Fabry Disease: Red Flags for Early Diagnosis of Cardiac Involvement

Prognostic role of ECG patterns in Anderson Fabry disease

Unraveling Novel Cardiovascular Risk Factors in Fabry Disease

Anderson-Fabry disease patients with anatomical heart hypertrophy express a higher degree of electrocardiographic hypertrophy compared to hypertrophic cardiomyopathy patients

A Non-Invasive Technique to Unveil Renal Implications in Anderson–Fabry Disease

A Rare Case of Fabry's Disease-Induced Cardiomyopathy: A Case Report and Review of the Literature

Ventricular arrhythmias and primary prevention of sudden cardiac death in Anderson-Fabry disease

Pathogenesis and Molecular Mechanisms of Anderson-Fabry Disease and Possible New Molecular Addressed Therapeutic Strategies

Renal ultrastructural findings in Anderson-Fabry disease

Screening for Fabry Disease in Patients with Hypertrophic Cardiomyopathy Using Cardiac Magnetic Resonance Imaging.

C60 MYOCARDIAL T1 MAPPING IN ANDERSON–FABRY DISEASE AND ITS CORRELATION WITH GENETIC ANOMALITIES

Does left ventricular function predict cardiac outcome in Anderson–Fabry disease?

Right Ventricular Myocardial Involvement in Anderson–Fabry Disease at Diagnosis: Evaluation with Three-Dimensional Strain Imaging

Molecular Pathogenesis of Central and Peripheral Nervous System Complications in Anderson-Fabry Disease

Use of T1 mapping in cardiac MRI for the follow-up of Fabry disease in a pediatric population

Gastrointestinal Involvement in Anderson-Fabry Disease: A Narrative Review